Hate leafleting has become an increasingly common means for extremist groups to espouse hateful messages and intimidate ...

On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: 泰爱®) in patients with ...

JLens, a Registered Investment Advisor (RIA) and Fund Sponsor of the JLens 500 Jewish Advocacy U.S. ETF (NYSE: TOV), today ...